文献速递产科母胎医学

低剂量阿司匹林预防子痫前期:疗效与种族和民族的关系

Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race.
PubMed 文献 · Am J Obstet Gynecol MFM · 2020-07-21

本研究为两项随机对照试验的二次分析,比较低危和高危孕妇服用阿司匹林与安慰剂后子痫前期的发生率,并按种族和民族分层。低危试验中,非西班牙裔白人服用阿司匹林后子痫前期风险显著降低(RR 0.19,95%CI 0.06-0.63,P=.007),其他种族组无差异;高危试验中各亚组均未见子痫前期发生率降低。

要点

  • 低危非西班牙裔白人孕妇服用阿司匹林可显著降低子痫前期风险。
  • 低危西班牙裔和非西班牙裔黑人孕妇中未观察到阿司匹林降低子痫前期风险。
  • 高危孕妇中各 ethnicity 和 race 亚组均未见阿司匹林降低子痫前期发生率。

核心结论

  • 低危非西班牙裔白人孕妇服用阿司匹林相比安慰剂可显著降低子痫前期发生率(P=.007),但总体、西班牙裔和非西班牙裔黑人中未见降低。
  • 高危孕妇分析未显示阿司匹林疗效因种族和民族而异。

研究设计与样本

  • 本研究为母婴医学单位网络(MFMU)两项随机对照试验(低危阿司匹林试验和高危阿司匹林试验)的二次分析。
  • 低危试验纳入3135名血压正常、未产妇女,孕13-26周随机接受每日60 mg阿司匹林或安慰剂。
  • 高危试验纳入2539名患有孕前胰岛素治疗糖尿病、慢性高血压、多胎妊娠或既往子痫前期病史的妇女,孕13-26周随机接受每日60 mg阿司匹林或安慰剂。

主要发现

  • 低危试验中,非西班牙裔白人服用阿司匹林组子痫前期风险显著低于安慰剂组(RR 0.19;95%CI 0.06-0.63;P=.007)。
  • 低危试验中,西班牙裔、非西班牙裔黑人及其他种族和民族组的阿司匹林组与安慰剂组子痫前期风险无差异。
  • 考虑依从性和随机化时孕周后,非西班牙裔白人中的疗效持续存在(RR 0.07;95%CI 0.009-0.51;P=.009)。
  • 低危试验中,阿司匹林组总体胎盘早剥风险较安慰剂组增加(P=.025)。
  • 低危试验中,非西班牙裔黑人服用阿司匹林组死产风险较安慰剂组显著增加(P=.048)。

关键数值与推荐

  • 低危试验非西班牙裔白人:阿司匹林 vs 安慰剂,子痫前期 RR 0.19(95%CI 0.06-0.63),P=.007。
  • 低危试验非西班牙裔白人(考虑依从性和随机化孕周):RR 0.07(95%CI 0.009-0.51),P=.009。
  • 低危试验阿司匹林组总体胎盘早剥风险增加,P=.025。
  • 低危试验非西班牙裔黑人阿司匹林组死产风险增加,P=.048。
  • 高危试验中各亚组子痫前期发生率比较均 P>.05。

临床怎么用

  • 对于低危非西班牙裔白人孕妇,低剂量阿司匹林可能显著降低子痫前期风险,但需权衡胎盘早剥风险。
  • 低危西班牙裔和非西班牙裔黑人孕妇中,阿司匹林预防子痫前期的获益未得到证实,且非西班牙裔黑人中死产风险增加需警惕。
  • 高危孕妇中,阿司匹林预防子痫前期的疗效未显示种族和民族差异,但仍需个体化评估。

局限性

  • 本研究为二次分析,原始试验并非按种族和民族分层设计。
  • 部分亚组样本量较小,统计效能有限。
  • 结果基于60 mg阿司匹林每日,可能不适用于其他剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose aspirin is recommended for the prevention of preeclampsia among women at a high risk of developing the disease. Aspirin undergoes polymorphic metabolism, and it is well known that common genetic polymorphisms are related to aspirin intolerance. We hypothesized that the efficacy of aspirin prophylaxis may differ by ethnicity and race. OBJECTIVE: This study aimed to compare the rates of preeclampsia among low- and high-risk women who received aspirin compared with placebo, stratifying results by ethnicity and race as a first-pass approximation of genomic polymorphisms. STUDY DESIGN: This is a secondary analysis of 2 randomized controlled trials previously performed by the Maternal-Fetal Medicine Units Network: the Low-Risk Aspirin trial and the High-Risk Aspirin trial. For the Low-Risk Aspirin trial, normotensive, nulliparous women were enrolled between 13 and 26 weeks' gestation and randomized to 60 mg aspirin daily or placebo. For the High-Risk Aspirin trial, women with pregestational insulin-treated diabetes mellitus, chronic hypertension, multiple gestations, or a history of preeclampsia in a previous pregnancy were enrolled between 13 and 26 weeks' gestation and randomized to 60 mg aspirin daily or placebo. The primary outcome of our secondary analysis was preeclampsia. Secondary outcomes included gestational age at delivery, preterm delivery, placental abruption, small for gestational age, stillbirth, and neonatal death. Outcomes were stratified by ethnicity and race (Hispanic, non-Hispanic white, non-Hispanic black, or other). RESULTS: In the Low-Risk Aspirin trial of 3135 women, the risk of preeclampsia was significantly reduced among non-Hispanic white women who received aspirin compared with non-Hispanic white women who received placebo (relative risk, 0.19; 95% confidence interval, 0.06-0.63; P=.007). The risk of preeclampsia was not different when comparing the aspirin and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and race groups. The efficacy among non-Hispanic white women persisted after consideration of compliance and gestational age at randomization (relative risk, 0.07; 95% confidence interval, 0.009-0.51; P=.009). As noted in the original trial, there was an increased risk of placental abruption in the aspirin group overall compared with placebo (P=.025). The risk of stillbirth was significantly increased among non-Hispanic black women who received aspirin compared with non-Hispanic black women who received placebo (P=.048). In the High-Risk Aspirin trial of 2539 women, 269 were Hispanic (10.6%), 832 were non-Hispanic white (32.8%), 1426 were non-Hispanic black (56.2%), and 12 were categorized as other (0.5%). Stratification by ethnicity and race did not reveal a decreased incidence of preeclampsia for any of the subgroups (P>.05). Moreover, there was no significant difference in other measured outcomes including preterm delivery at <37 weeks' gestation, placental abruption, small for gestational age, stillbirth, or neonatal death. CONCLUSION: The incidence of preeclampsia was significantly reduced among low-risk non-Hispanic white women who received aspirin compared with placebo (P=.007), but not overall or among Hispanic or non-Hispanic black women. The analysis of high-risk women did not indicate a difference in the efficacy of aspirin by ethnicity and race.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Tolcher MC, Sangi-Haghpeykar H, Mendez-Figueroa H, et al. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. Am J Obstet Gynecol MFM. 2020. PMID: 33345910. doi:10.1016/j.ajogmf.2020.100184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。